The FTC's Continuing Challenge to Reverse Payment Patent Settlements in the Pharmaceutical Industry By Helen Cho Eckert


In early 2009, the Federal Trade Commission (‘‘FTC’’) launched its latest challenge to reverse payment settlements in the pharmaceutical industry, FTC v. Watson Pharmaceuticals (‘‘Watson’’).1 In a press release accompanying Watson, the FTC announced that ‘‘’[t]oday’s action reaffirms the Commission’s commitment to protect American consumers from artificially high prescription drug prices that result when branded and generic pharmaceutical companies decide to collude rather than compete[.]’ ’’2 In a concurring statement, FTC Chairman Jon Leibowitz took it a step further, declaring that ‘‘eliminating these pay-for delay settlements is one of the most important objectives for antitrust enforcement in America today.’’3

Please see full article for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sheppard Mullin Richter & Hampton LLP | Attorney Advertising

Written by:


Sheppard Mullin Richter & Hampton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.